Phase 2 clinical trial: multicenter, double-blind, randomized, controlled |
1a |
high |
19,27 |
Clinical trial: single-center, randomized, double-blind, controlled |
1b |
moderate |
31 |
Phase 1 clinical trial: multicenter, open-label, randomized, controlled |
1b |
moderate |
33 |
Phase 1 clinical trial: single-center, double-blinded, randomized, controlled |
1b |
moderate |
14 |
Phase 1 clinical trial: multicenter, open-label, non-randomized, noncontrolled |
2b |
low |
26,38 |
Pilot trial: single-center, open-label, non-randomized, controlled |
2b |
low |
34 |
Phase 1 clinical trial: single-center, open-label, non-randomized, controlled |
2b |
low |
17 |
Clinical trial: multicenter, open-label, non-randomized, noncontrolled |
2b |
low |
32 |
Clinical trial: single-center |
|
|
|
open-label, randomized, controlled |
2b |
low |
18 |
Pilot trial: multicenter, open-label, non-randomized, noncontrolled |
2b |
low |
21,36 |
Clinical trial: single-center, open-label, non-randomized, noncontrolled |
2c |
low |
11,22,23,28,29 |
Pilot trial: single-center, open-label, non-randomized, noncontrolled |
2c |
low |
16 |
Cohort |
4c |
very low |
24 |
Case report |
4c |
very low |
13,20,24,30,35,37,63 |
Case series |
4c |
very low |
25 |